Floatz logo

Degarelix

Treatment

Changhai Hospitalprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Treatment cohort.

Asset / SponsorPhaseRating
Sodium Oligomannate
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B
CIS-DIAMMINEDICHLOROPLATINUM II
Peking Union Medical College Hospital
Phase 2B
Capecitabine
Henan Cancer Hospital
Phase 2CCC
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
University Hospital, Strasbourg, France
Phase 2CCC
Vinorelbine
Henan Cancer Hospital
Phase 2CCC

View all 10 →

Same molecule, other indications

Degarelix is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate cancerDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →